|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM58 |
Gene summary for TRIM58 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM58 | Gene ID | 25893 |
| Gene name | tripartite motif containing 58 | |
| Gene Alias | BIA2 | |
| Cytomap | 1q44 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8NG06 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25893 | TRIM58 | HCC1 | Human | Liver | HCC | 8.89e-29 | 2.27e+00 | 0.5336 |
| 25893 | TRIM58 | HCC2 | Human | Liver | HCC | 1.36e-48 | 3.15e+00 | 0.5341 |
| 25893 | TRIM58 | HCC5 | Human | Liver | HCC | 1.90e-56 | 2.78e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM58 | SNV | Missense_Mutation | c.1239N>G | p.Ile413Met | p.I413M | Q8NG06 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| TRIM58 | SNV | Missense_Mutation | rs565939415 | c.896N>T | p.Thr299Met | p.T299M | Q8NG06 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM58 | SNV | Missense_Mutation | novel | c.47G>T | p.Cys16Phe | p.C16F | Q8NG06 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A42V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM58 | SNV | Missense_Mutation | c.1082N>A | p.Gly361Glu | p.G361E | Q8NG06 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A15R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| TRIM58 | SNV | Missense_Mutation | novel | c.427N>T | p.Leu143Phe | p.L143F | Q8NG06 | protein_coding | tolerated(0.05) | possibly_damaging(0.56) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| TRIM58 | SNV | Missense_Mutation | novel | c.1285G>A | p.Asp429Asn | p.D429N | Q8NG06 | protein_coding | tolerated(0.45) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TRIM58 | SNV | Missense_Mutation | c.1066N>T | p.Ala356Ser | p.A356S | Q8NG06 | protein_coding | tolerated(0.2) | benign(0.05) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM58 | SNV | Missense_Mutation | novel | c.1370N>C | p.Ile457Thr | p.I457T | Q8NG06 | protein_coding | tolerated(0.84) | benign(0.019) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| TRIM58 | SNV | Missense_Mutation | c.1369A>T | p.Ile457Phe | p.I457F | Q8NG06 | protein_coding | deleterious(0.02) | possibly_damaging(0.812) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TRIM58 | SNV | Missense_Mutation | c.1154N>T | p.Trp385Leu | p.W385L | Q8NG06 | protein_coding | tolerated(0.12) | possibly_damaging(0.836) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |